Early Detection Cognivue offers FDA-cleared cognitive assessment technology with rapid results, enabling clinics to integrate routine screening for early detection of cognitive changes, presenting an upsell opportunity to practices expanding preventive care services.

Amyloid Risk Launch of Cognivue Amyloid Risk Measure (CARM) provides a biomarker-focused add-on that can attract neurology and primary care practices seeking to stratify dementia risk and potentially upsell more comprehensive diagnostic pathways.

Market Leadership Recognition as a top cognitive impairment early detection solution and ongoing device upgrades position Cognivue as a preferred partner for healthcare providers prioritizing validated, scalable cognitive assessment tools.

Partnerships Strategic collaborations, such as with LearningRx, indicate a channel-friendly approach that can be extended to senior care networks, cognitive training centers, and outpatient clinics seeking integrated cognitive health solutions.

Growth Readiness Recent leadership expansion and next-generation device launches signal readiness for market expansion and adoption in new healthcare settings, presenting opportunities to target mid-market hospital systems and specialty clinics seeking scalable deployment.